AZNNYSEPharmaceutical PreparationsFiscal year ends December 31
ASTRAZENECA PLC
Financials through fiscal 2025, year ended Dec 31, 2025
$163.95−1.46 (-0.88%)
Close on Oct 19, 2026
- Market cap
- –
- P/E (TTM)
- 25.1
- Dividend yield
- 1.91%
Share price
−$5.43 (−3.21%)past year
Daily closes, adjusted for splits. Drag across the chart to measure a change.Ex-dividendSplit
ASTRAZENECA PLC grew revenue 8.6% to $58.74B over fiscal 2025. Operating income rose 37.4% to $13.74B, moving the operating margin from 18.5% to 23.4%. Free cash flow was $11.77B, up 18.4% from a year earlier.
Revenue
$58.74B
+8.6% vs. a year earlier
Operating income
$13.74B
+37.4% vs. a year earlier
Free cash flow
$11.77B
+18.4% vs. a year earlier
EPS, diluted
$6.54
+45.3% vs. a year earlier
Key statistics
Valuation at the latest close; fundamentals over fiscal 2025, balances at Dec 31, 2025
Valuation
- Market cap
- –
- P/E ratio
- 25.1
- Price to sales
- –
- Price to book
- –
- Dividend yield
- 1.91%
- Free cash flow yield
- –
Fundamentals
- Revenue
- $58.74B
- Net income
- $10.23B
- EPS, diluted
- $6.54
- Free cash flow
- $11.77B
Eleven years at a glance
Fiscal years 2015 to 2025, USD
Revenue
$58.74B+8.6% YoY
Gross profit
$48.11B+9.7% YoY
Operating income
$13.74B+37.4% YoY
Net income
$10.23B+45.3% YoY
EPS, diluted
$6.54+45.3% YoY
Free cash flow
$11.77B+18.4% YoY
Reported period